GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

NCT05557578 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG: Tislelizumab combined with GEMOX (GOT) regimen

Sponsor

Zhejiang Cancer Hospital